Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases

World Journal of Gastroenterology : WJG
Jason ReinglasPéter László Lakatos

Abstract

The past decade has brought substantial advances in the management of inflammatory bowel diseases (IBD). The introduction of tumor necrosis factor (TNF) antagonists, evidence for the value of combination therapy, the recognition of targeting lymphocyte trafficking and activation as a viable treatment, and the need for early treatment of high-risk patients are all fundamental concepts for current modern IBD treatment algorithms. In this article, authors review the existing data on approved biologicals and small molecules as well as provide insight on the current positioning of approved therapies. Patient stratification for the selection of specific therapies, therapeutic targets and patient monitoring will be discussed as well. The therapeutic armamentarium for IBD is expanding as novel and more targeted therapies become available. In the absence of comparative trials, positioning these agents is becoming difficult. Emerging concepts for the future will include an emphasis on the development of algorithms which will facilitate a greater understanding of the positioning of novel biological drugs and small molecules in order to best tailor therapy to the patient. In the interim, anti-TNF therapy remains an important component of I...Continue Reading

References

Sep 28, 1989·The New England Journal of Medicine·J BrynskovM C Campanini
Sep 29, 1994·The New England Journal of Medicine·P RutgeertsH Lorenz-Meyer
Jun 30, 1994·The New England Journal of Medicine·S LichtigerS Hanauer
Jun 6, 2002·Lancet·Stephen B HanauerUNKNOWN ACCENT I Study Group
Aug 2, 2003·Journal of the American Academy of Dermatology·Alice B Gottlieb
Feb 6, 2004·Gastroenterology·Paul RutgeertsStephen B Hanauer
Feb 27, 2004·The New England Journal of Medicine·Bruce E SandsSander J van Deventer
Mar 9, 2005·World Journal of Gastroenterology : WJG·Elena UrcelayEmilio-G de la Concha
Jun 11, 2005·The New England Journal of Medicine·Annette Langer-GouldDaniel Pelletier
Jun 11, 2005·The New England Journal of Medicine·B K Kleinschmidt-DeMasters, Kenneth L Tyler
Jun 11, 2005·The New England Journal of Medicine·Gert Van AsschePaul Rutgeerts
Sep 7, 2005·Gastroenterology·Stefan SchreiberUNKNOWN CDP870 Crohn's Disease Study Group
Nov 4, 2005·The New England Journal of Medicine·William J SandbornUNKNOWN Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group
Dec 13, 2005·The New England Journal of Medicine·Paul RutgeertsJean Frédéric Colombel
Apr 19, 2006·Gastroenterology·Marc LémannUNKNOWN Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID)
May 2, 2007·Annals of Internal Medicine·William J SandbornPaul F Pollack
May 9, 2007·Gastroenterology·Stephan R TarganUNKNOWN International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group
Jun 9, 2007·The American Journal of Gastroenterology·Ole HöieUNKNOWN European Collaborative Study Group of Inflammatory Bowel Disease (EC-IBD)
Jul 20, 2007·The New England Journal of Medicine·William J SandbornUNKNOWN PRECISE 1 Study Investigators
Jul 20, 2007·The New England Journal of Medicine·Stefan SchreiberUNKNOWN PRECISE 2 Study Investigators
Dec 7, 2007·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Inger Camilla SolbergUNKNOWN IBSEN Study Group
Aug 30, 2008·Therapeutics and Clinical Risk Management·Eihab A AlwawiKenneth B Gordon
Jan 22, 2010·The Cochrane Database of Systematic Reviews·John K MarshallE Jan Irvine
Feb 2, 2010·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Gary R LichtensteinUNKNOWN Precise 3 Study Investigators
Apr 16, 2010·The New England Journal of Medicine·Jean Frédéric ColombelUNKNOWN SONIC Study Group
Jun 3, 2010·World Journal of Gastroenterology : WJG·Peter Laszlo Lakatos
Mar 17, 2011·The American Journal of Gastroenterology·Alexander C FordPaul Moayyedi
Mar 17, 2011·The American Journal of Gastroenterology·Alexander C FordPaul Moayyedi
Apr 11, 2012·Health Technology Assessment : HTA·H YangN Woolacott

❮ Previous
Next ❯

Citations

Apr 25, 2019·Current Gastroenterology Reports·Tushar Shukla, Bruce E Sands
Jul 20, 2019·Drug Development Research·Elena MilanesiMircea Manuc
Aug 3, 2019·Expert Opinion on Biological Therapy·Irene MarafiniGiovanni Monteleone
Sep 27, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Edvin BrusačAna Mornar
Nov 20, 2019·Journal of Crohn's & Colitis·Michel AdaminaOded Zmora
Jan 25, 2019·Visceral Medicine·Peter Kienle
Aug 3, 2020·Gastroenterology Nursing : the Official Journal of the Society of Gastroenterology Nurses and Associates·Cynthia MorvilloSteven Stein
Feb 13, 2020·F1000Research·Simon P Borg-BartoloRahul Kalla
Oct 25, 2020·The Cochrane Database of Systematic Reviews·Cindy Cy LawNeeraj Narula
Mar 13, 2021·International Journal of Pharmaceutics·Wenjuan LiuZhongjian Chen
Oct 22, 2021·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Bob Geng, Timothy J Craig

❮ Previous
Next ❯

Software Mentioned

ENCORE
DOWN
PLANETRA
ACCENT
PLANETAS
EXTEND
GETAID
GEMINI
OCTAVE
TOP

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.